S28 Benefits observed with patient-reported outcomes in a phase 2b clinical trial of gefapixant, a P2X3 receptor antagonist, in chronic cough
Published: Nov 12, 2019
Abstract
Background
The negative impact of chronic cough on patients’ daily lives is multi-faceted; therefore, the evaluation of chronic cough treatment requires an approach including both objective and subjective measures. We assessed patient-reported outcomes (PROs) in a phase 2b clinical trial of gefapixant in patients with refractory or unexplained chronic cough (RCC or UCC).Methods
This Phase 2b, 12-week, randomized controlled...Paper Details
Title
S28 Benefits observed with patient-reported outcomes in a phase 2b clinical trial of gefapixant, a P2X3 receptor antagonist, in chronic cough
Published Date
Nov 12, 2019
Citation AnalysisPro
You’ll need to upgrade your plan to Pro
Looking to understand the true influence of a researcher’s work across journals & affiliations?
- Scinapse’s Top 10 Citation Journals & Affiliations graph reveals the quality and authenticity of citations received by a paper.
- Discover whether citations have been inflated due to self-citations, or if citations include institutional bias.
Notes
History